Clinical Trial Update: Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating safety and tolerability of switching to ITCA 650 in patients with type 2 diabetes currently receiving liraglutide.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• ITCA 650
• liraglutide (liraglutide)

Snippet

Sponsor: Intarcia Therapeutics | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED